1

. بر

LEGISLATIVE HISTORY CHECKLIST

NJSA:	17:48-6d; 17:48E-35.1		(Hemophilia home treatment include in Blue Cross coverage)
Laws Of:	1987		CHAPTER 62
Bill No:	A1095		
Sponsor(s): Ogden			
Date Introduced: Pre-filed			
Committee: Assembly:		Insurance	
	Senate:	Labor, Industry and	Professions
Amended during passage:		Yes	Substituted for S2262 (attached)
Date of Passage:		Assembly:	September 8, 1986
		Senate:	February 2, 1987
Date of Approval: March 10, 1987			a martiner
Following statements are attached if available:			
Sponsor sta	atement:		Yes
Committee statement:		Assembly	Yes
		Senate	Yes B
Fiscal Note:			No
Veto Message:			No
Message on Signing:			No
Following were printed:			
Reports:			No
Hearings:			No
			and a set of the set o

62 3-10-87 87

1

[OFFICIAL COPY REPRINT] ASSEMBLY, No. 1095 ______ STATE OF NEW JERSEY

PRE-FILED FOR INTRODUCTION IN THE 1986 SESSION

By Assemblywoman OGDEN

AN ACT providing for the inclusion of benefits for expenses incurred in connection with the purchase of blood products for home treatment of hemophilia in hospital service corporation contracts * and health service corporation contracts* and supplementing * [Title 17 of the Revised Statutes] * *P. L. 1938, c. 366 (C.17:48-1 et seq.) and P. L. 1985, c. 236 (C. 17:48E-1 et seq.)*.

1 BE IT ENACTED by the Senate and General Assembly of the State 2 of New Jersey:

1. *[No]* *Every* group or individual contract providing hos-1 $\mathbf{2}$ pital expense benefits * shall be delivered, issued, executed or renewed in this State, or approved for issuance or renewal in this 3 4 State by the Commissioner of Insurance after the effective date 5of this act, unless the contract provides benefits]* to any subscriber or other person covered thereunder for expenses incurred in con-6 7 nection with *the treatment of routine bleeding episodes associated 8 with hemophilia shall provide benefits for expenses incurred in 9 connection with* the purchase of blood products and blood infusion 10 equipment required for home treatment of routine bleeding episodes 11 associated with hemophilia when the home treatment program is under the supervision of a State approved hemophilia treatment 12center. The benefits shall be provided to the same extent as for 13 any sickness under the contract. 14 As used in this act, "blood product" includes, but is not limited 15to*,* Factor VIII, Factor IX and cryoprecipitate*;* and "blood 16

17 infusion equipment'' includes, but is not limited to^{*},^{*} syringes and 18 needles.

EXPLANATION—Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted in the law. Matter printed in italics *thus* is new matter.

Matter enclosed in asterisks or stars has been adopted as follows: *--- Assembly committee amendments adopted May 8, 1986. 19Participation in a home treatment program shall not preclude 20further or additional treatment or care at any eligible facility if the number of *home* treatments, in accordance with a ratio of 2122*home* treatments to benefit days established by regulation by the 23Commissioner of Insurance, does not exceed the total number of benefit days provided for any other sickness under the contract. 24*2. Every group or individual contract providing hospital ex-1 $\mathbf{2}$ pense benefits to any subscriber or other person covered thereunder 3 for expenses incurred in connection with the treatment of routine bleeding episodes associated with hemophilia shall provide benefits 4 $\mathbf{5}$ for expenses incurred in connection with the purchase of blood 6 products and blood infusion equipment required for home treatment of routine bleeding episodes associated with hemophilia when the 7home treatment program is under the supervision of a State ap-8 proved hemophilia treatment center. The benefits shall be pro-9vided to the same extent as any other sickness under the contract. 10As used in this act, "blood product" includes, but is not limited 11 12to Factor VIII, Factor IX and cryoprecipitate; and "blood infusion equipment" includes, but is not limited to, syringes and needles. 13Parficipation in a home treatment program shall not preclude 14further or additional treatment or care at any eligible facility if 15the number of home treatments, in accordance with a ratio of home 16treatments to benefit days established by regulation by the Com-17missioner of Insurance, does not exceed the total number of benefit 1819days provided for any other sickness under the contract.*

1 *[2. This]* *3. Sections 1 and 2 of this* act shall apply to all 2 contracts in which the insurer reserves the right to change the 3 premium.

1 ***[3.]*** *4.* This act shall take effect immediately.

INSURANCE—HEALTH AND LIFE

Provides for inclusion of certain blood products and equipment for home treatment of hemolphilia in hospital service corporation and health service corporation contracts.

ASSEMBLY, No. 1095

Introduced Pending Technical Review by Legislative Counsel PRE-FILED FOR INTRODUCTION IN THE 1986 SESSION By Assemblywoman OGDEN

ASSEMBLY, No. 1786 STATE OF NEW JERSEY

INTRODUCED APRIL 30, 1984

By Assemblyman GALLO

- An Acr providing for the inclusion of benefits for expenses incurred in connection with the purchase of blood products for home treatment of hemophilia in hospital service corporation contracts and supplementing Title 17 of the Revised Statutes.
- 1 BE IT ENACTED by the Senate and General Assembly of the State 2 of New Jersey:

1 1. No group or individual contract providing hospital expense 2benefits shall be delivered, issued, executed or renewed in this 3 State, or approved for issuance or renewal in this State by the 4 Commissioner of Insurance after the effective date of this act, 5unless the contract provides benefits to any subscriber or other 6 person covered thereunder for expenses incurred in connection with $\overline{7}$ the purchase of blood products and blood infusion equipment re-8 quired for home treatment of routine bleeding episodes associated 9 with hemophilia when the home treatment program is under the 10supervision of a State approved hemophilia treatment center. The benefits shall be provided to the same extent as for any sickness 11 12under the contract.

- As used in this act, "blood product" includes, but is not limited
 to Factor VIII, Factor IX and cryoprecipitate and "blood infusion
 equipment" includes, but is not limited to syringes and needles.
- 16 Participation in a home treatment program shall not preclude 17 further or additional treatment or care at any eligible facility if
- 18 the number of treatments, in accordance with a ratio of treatments
- 19 to benefit days established by regulation by the Commissioner of

- 21 vided for any other sickness under the contract.
- 1 2. This act shall apply to all contracts in which the insurer re-2 serves the right to change the premium.
- 1 3. This act shall take effect immediately.

STATEMENT

Recent advances in the treatment of hemophilia have resulted in new and cost effective means for treating routine bleeding episodes in the home. Under the supervision of specialized hemophilia treatment centers, properly trained hemophilia patients or family members can administer needed blood concentrates at home to control routine bleeding episodes. The home treatment programs have been shown to reduce the number of visits to hospital emergency rooms or outpatient clinics, the number of days required for hospitalization, the number of days lost from work or school and potentially, the need for long-term, costly rehabilitative therapy.

Since hemophiliacs traditionally have been treated in hospital settings, both inpatient and outpatient, basic health insurance policies are designed to provide coverage for needed blood products when they are administered in the hospital. The same blood products are not covered under the basic policies when they are administered at home. In recognition of the advances made in treatment of hemophilia, this bill mandates coverage in all hospital service corporation contracts for blood products and equipment needed for infusion of the blood products when the blood products are administered at home under the supervision of a State approved hemophilia treatment center.

While the cost of purchasing needed blood products for a hemophiliac may be substantial to an individual or his family, the total increase in health insurance costs for mandated coverage of home treatment will be insignificant since very few individuals in the State need or use the blood product and home treatment for routine bleeding episodes is less costly than similar treatment which otherwise would be provided in a hospital.

A10 95 (1987)

SENATE, No. 2262 STATE OF NEW JERSEY

∥ i

INTRODUCED JUNE 12, 1986

By Senator LYNCH

Referred to Committee on Labor, Industry and Professions

An Act providing for the inclusion of benefits for expenses incurred in connection with the purchase of blood products for home treatment of hemophilia in hospital service corporation contracts and health service corporation contracts and supplementing P. L. 1938, c. 366 (C. 17:48–1 et seq.) and P. L. 1985, c. 236 (C. 17:48E–1 et seq.).

1 BE IT ENACTED by the Senate and General Assembly of the State 2 of New Jersey:

1 1. Every group or individual contract providing hospital expense $\mathbf{2}$ benefits to any subscriber or other person covered thereunder for 3 expenses incurred in connection with the treatment of routine 4 bleeding episodes associated with hemophilia shall provide benefits for expenses incurred in connection with the purchase of blood 56 products and blood infusion equipment required for home treat-7ment of routine bleeding episodes associated with hemophilia when 8 the home treatment program is under the supervision of a State approved hemophilia treatment center. The benefits shall be pro-9 vided to the same extent as for any sickness under the contract. 10

11 As used in this act, "blood product" includes, but is not limited 12 to, Factor VIII, Factor IX and cryoprecipitate; and "blood in-13 fusion equipment" includes, but is not limited to, syringes and 14 needles.

15 Participation in a home treatment program shall not preclude 16 further or additional treatment or care at any eligible facility if 17 the number of home treatments, in accordance with a ratio of home 18 treatments to benefit days established by regulation by the Com-19 missioner of Insurance, does not exceed the total number of benefit 20 days provided for any other sickness under the contract.

1 2. Every group or individual contract providing hospital expense $\mathbf{2}$ benefits to any subscriber or other person covered thereunder for 3 expenses incurred in connection with the treatment of routine 4 bleeding episodes associated with hemophilia shall provide benefits for expenses incurred in connection with the purchase of blood 56 products and blood infusion equipment required for home treat-7 ment of routine bleeding episodes associated with hemophilia when 8 the home treatment program is under the supervision of a State 9 approved hemophilia treatment center. The benefits shall be pro-10 vided to the same extent as any other sickness under the contract. As used in this act, "blood product" includes, but is not limited 11 to Factor VIII, Factor IX and cryoprecipitate; and "blood infusion 12equipment" includes, but is not limited to, syringes and needles. 13Participation in a home treatment program shall not preclude 14 15further or additional treatment or care at any eligible facility if the number of home treatments, in accordance with a ratio of home 16treatments to benefit days established by regulation by the Com-17 missioner of Insurance, does not exceed the total number of benefit 18 days provided for any other sickness under the contract. 19

1 3. Sections 1 and 2 of this act shall apply to all contracts in which 2 the insurer reserves the right to change the premium.

1 4. This act shall take effect immediately.

STATEMENT

This bill, amending the laws governing hospital service corporations and health service corporations, would require that contracts issued by the corporations which provide benefits for inpatient treatment for hemophilia also provide benefits for home treatment.

INSURANCE—LIFE AND HEALTH Provides for benefits for the home treatment of hemophilia. ASSEMBLY INSURANCE COMMITTEE

STATEMENT ON

Assembly, Bill No. 1095 Aca

DATED: May 8, 1986

As amended by the Assembly Insurance Committee, this bill would require that every group and individual hospital service corporation contract which provides benefits to subscribers for expenses incurred in connection with the treatment of hemophilia also provide benefits for the purchase of blood products and blood infusion equipment which is required for the home treatment of routine bleeding episodes associated with hemophilia. The home treatment would be required to be under the supervision of a State approved hemophilia treatment center. The benefits would be required to be provided to the same extent as any other illness under the contract, in accordance with a ratio of treatment-to-benefit days which is established by the Commissioner of Insurance by regulation.

The purpose of the bill is to establish a less expensive, alternative treatment for hemophilia than hospital inpatient care. Some insurers already provide for outpatient hemophilia treatment for their group clients on an elective basis, because they believe that the program is cost-effective.

The committee amendments add a section of law which supplements the law creating health service corporations, P. L. 1985, c. 386, so that the merged Blue Cross and Blue Shield will be covered by the legislation.

SENATE LABOR, INDUSTRY AND PROFESSIONS COMMITTEE

STATEMENT TO

ASSEMBLY, No. 1095

[OFFICIAL COPY REPRINT]

STATE OF NEW JERSEY

DATED: OCTOBER 27, 1986

This bill, which supplements the laws governing hospital service corporations and health service corporations, would require that every group and individual contract issued by the corporations which provides benefits to subscribers for expenses incurred in connection with the treatment of hemophilia also provide benefits for the purchase of blood products and blood infusion equipment which is required for the home treatment of routine bleeding episodes associated with hemophilia. The home treatment would be required to be under the supervision of a State approved hemophilia treatment center. The benefits would be required to be provided to the same extent as for any other sickness under the contract, in accordance with a ratio of treatment-to-benefit days which is established by the Commissioner of Insurance by regulation.